Published in Biologics on May 25, 2010
Psoriasis Longitudinal Assessment and Registry (PSOLAR) | NCT00508547
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. AAPS J (2015) 0.76
An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. AAPS J (2015) 0.75
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
Psoriasis. N Engl J Med (2009) 8.80
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis (2004) 6.54
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol (2008) 6.09
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 4.58
Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 4.24
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet (2006) 4.22
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol (2005) 3.18
Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med (2007) 2.89
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol (2001) 2.52
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis (2005) 2.33
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (2005) 1.99
The psychosocial burden of psoriasis. Am J Clin Dermatol (2005) 1.81
Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis (2005) 1.58
Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy (2004) 1.58
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 1.51
Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol (2002) 1.50
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol (2008) 1.46
Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol (2010) 1.24
Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med (2007) 1.20
Complexity of the association between psoriasis and comorbidities. J Invest Dermatol (2009) 1.19
Anti-TNF-induced lupus. Rheumatology (Oxford) (2009) 1.12
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin (2007) 1.11
IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol (2009) 1.09
Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther (2006) 1.06
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol (2009) 1.03
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci (2009) 0.97
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis (2006) 0.97
Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology (2000) 0.96
Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis. Rheumatol Int (2009) 0.89
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol (2009) 0.88
Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today (2009) 0.87
Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol (2007) 0.87
Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol (2006) 0.85
Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit Rev Immunol (1997) 0.84
Ustekinumab for psoriatic arthritis. Lancet (2009) 0.80
Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol (2010) 0.79
'Biologics': a clinically meaningless term. Br J Dermatol (2006) 0.76
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol (2007) 3.58
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis (2010) 1.85
Number of nevi at a specific anatomical site and its relation to cutaneous malignant melanoma. J Invest Dermatol (2006) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol (2002) 1.44
Prediction of clinical response to excimer laser treatment in vitiligo by using neural network models. Dermatology (2009) 1.40
Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res (2010) 1.30
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28
The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics (2012) 1.18
Tobacco and skin disease. Dermatology (2005) 1.15
Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res (2006) 1.14
Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol (2010) 1.09
Chronic pruritus management: a plea for improvement--can itch clinics be an option? Dermatology (2010) 1.05
Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol (2009) 1.04
Congenital melanocytic nevus: an epidemiologic study in Italy. Dermatology (2007) 1.00
Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol (2012) 0.99
Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol (2007) 0.97
The density of melanocytic nevi correlates with constitutional variables and history of sunburns: a prevalence study among Italian schoolchildren. Int J Cancer (2002) 0.97
Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol (2011) 0.96
Removal of tattoos by q-switched laser: variables influencing outcome and sequelae in a large cohort of treated patients. Arch Dermatol (2012) 0.94
Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis (2011) 0.91
Risk factors for histological types and anatomic sites of cutaneous basal-cell carcinoma: an italian case-control study. J Invest Dermatol (2006) 0.91
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol (2015) 0.87
Nevus count on specific anatomic sites as a predictor of total body count: a survey of 3,406 children from Italy. Am J Epidemiol (2007) 0.87
Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients. J Med Virol (2012) 0.86
Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? Melanoma Res (2004) 0.86
Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol (2006) 0.85
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol (2006) 0.81
Health-related quality of life: from health economics to bedside? Dermatology (2007) 0.81
Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study. Dermatology (2008) 0.81
Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study. Dermatology (2014) 0.81
Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res (2011) 0.81
Prevalence and risk factors for superficial fungal infections among Italian Navy Cadets. Dermatology (2004) 0.80
Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol (2006) 0.79
[Seborrheic dermatitis in clinical practice]. Recenti Prog Med (2011) 0.78
Frequency of X-linked ichthyosis in coastal southern Italy: a study on a representative sample of a young male population. Dermatology (2003) 0.78
The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol (2009) 0.78
Longitudinal study of seroprevalence and serostability of 34 human papillomavirus types in European organ transplant recipients. Virology (2012) 0.78
A new era in the management of psoriasis? Promises and facts. Dermatology (2005) 0.77
Red hairs, number of nevi, and risk of cutaneous malignant melanoma: results from a case-control study in Italy. Arch Dermatol (2006) 0.76
A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology (2002) 0.76
Conflicts of interest in dermatology. Acta Derm Venereol (2006) 0.76
Psoriasis. N Engl J Med (2005) 0.75
Longitudinal studies of melanocytic nevi in children: a clue to improve understanding of melanoma in adults. Arch Dermatol (2009) 0.75
Parental Use and Educational Campaigns on Sunbed Use Among Teenagers and Adolescents. Medicine (Baltimore) (2016) 0.75
Should we use body mass index to predict disease onset and severity in psoriasis? Acta Derm Venereol (2009) 0.75
Vitiligo. N Engl J Med (2009) 0.75
No Association Between Vitiligo and Obesity: A Case-control Study. Med Princ Pract (2017) 0.75
[Free drug samples for doctors? no, thank you!]. Recenti Prog Med (2014) 0.75
Reproducibility of dermoscopic features of congenital melanocytic nevi. Dermatology (2008) 0.75
Variables affecting clinical response to treatment of facial port-wine stains by flash lamp-pumped pulsed dye laser: the importance of looking beyond the skin. Lasers Med Sci (2014) 0.75
Dermoscopic features of congenital melanocytic nevus and Becker nevus in an adult male population: an analysis with a 10-fold magnification. Dermatology (2006) 0.75
Analysis of the 3'UTR of the prostaglandin synthetase-2 (PTGS-2/COX-2) gene in non-melanoma skin cancer after organ transplantation. Exp Dermatol (2011) 0.75
Perinatal factors and the risk of atopic dermatitis: a cohort study. Pediatr Allergy Immunol (2013) 0.75
Counting genetic skin disease in the population. Dermatology (2003) 0.75
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Acta Derm Venereol (2016) 0.75
To what extent is quality of life impaired in vitiligo? A multicenter study on Italian patients using the dermatology life quality index. Dermatology (2014) 0.75
Double-blind, within-patient, randomized, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar psoriasis. J Dermatolog Treat (2012) 0.75
Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. Clin Transplant (2009) 0.75
Evidence-based dermatology: a need to reset the agenda. Dermatology (2002) 0.75
Double-blind placebo-controlled randomized clinical trial on the efficacy of Aerosal in the treatment of sub-obstructive adenotonsillar hypertrophy and related diseases. Int J Pediatr Otorhinolaryngol (2013) 0.75
Double phase treatment with flashlamp-pumped pulsed-dye laser and long pulsed Nd:YAG laser for resistant port wine stains in adults. Preliminary reports. G Ital Dermatol Venereol (2016) 0.75
X-linked ichthyosis in southern Italy. J Am Acad Dermatol (2003) 0.75
Design and feasibility of an international study assessing the prevalence of contact allergy to fragrances in the general population: the European Dermato-Epidemiology Network Fragrance Study. Dermatology (2010) 0.75
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. J Drugs Dermatol (2017) 0.75
Malignant melanoma in a candidate for heart transplantation. Dermatology (2005) 0.75
Melanoma management in Italy: learning from practice. A survey from the Intergruppo Italiano Melanoma. Dermatology (2013) 0.75
The +61 A-G polymorphism of the epidermal growth factor gene is not associated with occurrence of non-melanocytic skin tumors in transplant recipients. J Dermatol Sci (2007) 0.75
Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis. Dermatology (2014) 0.75